Literature DB >> 10233489

A prospective randomized controlled trial of hybrid laser treatment or transurethral resection of the prostate, with a 1-year follow-up.

A Carter1, H Sells, M Speakman, P Ewings, R MacDonagh, P O'Boyle.   

Abstract

OBJECTIVE: To compare the clinical outcome after hybrid laser treatment of the prostate, combining potassium titanyl phosphate (KTP) and Nd:YAG lasers, with transurethral resection of the prostate (TURP). PATIENTS AND METHODS: A prospective randomized trial was conducted to compare laser treatment and TURP. The hybrid laser treatment technique involved performing initial 30 W KTP vaporizing bladder neck incisions and prostatotomies followed by a 'free-paint' application of 60 W Nd:YAG coagulation energy. Patients were re-assessed after 6 weeks, 6 months and 1 year, using the International Prostate Symptom Score (IPSS) and uroflowmetry. TURP was conducted using conventional methods.
RESULTS: In all, 204 patients were randomized into the study; at 6 weeks there were significant differences between the groups for the IPSS (12.4 vs 9.1, P=0.001) and maximum urinary flow rates (16.1 vs 20.8 mL/S, P<0. 001) in favour of the TURP group. At 6 months and one year this difference had disappeared. Similar numbers of patients in each group complained of bothersome postoperative urinary symptoms (23% vs 19%). Blood transfusions (5% vs none) and urethral strictures (9% vs 2%) were more common after TURP, whereas more early infective complications occurred after hybrid laser treatment (24% vs 5%). Only one patient in each group required re-operation because of poor resolution of symptoms.
CONCLUSIONS: At one year, hybrid KTP/Nd:YAG laser treatment of the prostate was equivalent to TURP in the improvements in IPSS, maximum urinary flow rate and post-void residual urine.

Entities:  

Mesh:

Year:  1999        PMID: 10233489     DOI: 10.1046/j.1464-410x.1999.00936.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  9 in total

Review 1.  Benign prostatic hyperplasia.

Authors:  M J Barry; C G Roehrborn
Journal:  BMJ       Date:  2001-11-03

Review 2.  The evolution of photoselective vaporization prostatectomy (PVP): advancing the surgical treatment of benign prostatic hyperplasia.

Authors:  Richard Lee; Ricardo R Gonzalez; Alexis E Te
Journal:  World J Urol       Date:  2006-05-13       Impact factor: 4.226

3.  New techniques for laser prostatectomy: an update.

Authors:  Doreen E Chung; Alexis E Te
Journal:  Ther Adv Urol       Date:  2009-06

4.  Benign Prostatic Hyperplasia Treatment by Transurethral Enucleation of the Prostate Using a 2-μm Laser.

Authors:  He-Qing Guo; Gao-Biao Zhou; Hong-Ming Liu; Bin Sun; Guang-Xin Pan; Da-Wei Mu; Jing-Ming Yan; Ji-Zhang Xing; Di Li; Quan Hong
Journal:  Indian J Surg       Date:  2015-06-12       Impact factor: 0.656

Review 5.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  The use of lasers in benign prostatic enlargement.

Authors:  T A McNicholas; S Singh
Journal:  Curr Urol Rep       Date:  2000-08       Impact factor: 3.092

7.  Effectiveness and Safety of Photoselective Vaporization of the Prostate with the 120 W HPS Greenlight Laser in Benign Prostatic Hyperplasia Patients Taking Oral Anticoagulants.

Authors:  Jun Ho Sohn; Yong Sun Choi; Su Jin Kim; Hyuk Jin Cho; Sung Hoo Hong; Ji Youl Lee; Tae-Kon Hwang; Sae Woong Kim
Journal:  Korean J Urol       Date:  2011-03-18

Review 8.  The evolution of KTP laser vaporization of the prostate.

Authors:  Petros Sountoulides; Peter Tsakiris
Journal:  Yonsei Med J       Date:  2008-04-30       Impact factor: 2.759

9.  Different lasers in the treatment of benign prostatic hyperplasia: a network meta-analysis.

Authors:  Xingming Zhang; Pengfei Shen; Qiying He; Xiaoxue Yin; Zhibin Chen; Haojun Gui; Kunpeng Shu; Qidun Tang; Yaojing Yang; Xiuyi Pan; Jia Wang; Ni Chen; Hao Zeng
Journal:  Sci Rep       Date:  2016-03-24       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.